Aptevo Therapeutics (APVO) Operating Leases (2019 - 2023)
Historic Operating Leases for Aptevo Therapeutics (APVO) over the last 5 years, with Q3 2023 value amounting to $5.6 million.
- Aptevo Therapeutics' Operating Leases fell 1021.32% to $5.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was $5.6 million, marking a year-over-year decrease of 1021.32%. This contributed to the annual value of $6.1 million for FY2022, which is 35488.44% up from last year.
- Per Aptevo Therapeutics' latest filing, its Operating Leases stood at $5.6 million for Q3 2023, which was down 1021.32% from $5.7 million recorded in Q2 2023.
- Aptevo Therapeutics' 5-year Operating Leases high stood at $6.4 million for Q2 2022, and its period low was $1.1 million during Q1 2022.
- In the last 5 years, Aptevo Therapeutics' Operating Leases had a median value of $3.3 million in 2019 and averaged $3.7 million.
- As far as peak fluctuations go, Aptevo Therapeutics' Operating Leases plummeted by 4808.87% in 2022, and later surged by 43781.82% in 2023.
- Quarter analysis of 5 years shows Aptevo Therapeutics' Operating Leases stood at $3.3 million in 2019, then decreased by 29.07% to $2.4 million in 2020, then plummeted by 43.18% to $1.3 million in 2021, then skyrocketed by 354.88% to $6.1 million in 2022, then decreased by 8.2% to $5.6 million in 2023.
- Its Operating Leases stands at $5.6 million for Q3 2023, versus $5.7 million for Q2 2023 and $5.9 million for Q1 2023.